Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Roughly,000 actors 5 times of age and aged will be enrolled in Lyme complaint-aboriginal regions in Europe and theU.S.
NEW YORK & SAINT- HERBLAIN, France–( BUSINESS WIRE)– PfizerInc.( NYSE PFE) and Valneva SE( Nasdaq VALN; Euronext Paris VLA) moment blazoned the inauguration of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists( VALOR)( NCT05477524), to probe the efficacity, safety and immunogenicity of their investigational Lyme complaint vaccine seeker, VLA15.

“ With adding global rates of Lyme complaint, furnishing a new option for people to help cover themselves from the complaint is more important than ever, ” said Annaliesa Anderson,Ph.D., elderly Vice President and Head of Vaccine Research & Development at Pfizer. “ We hope that the data generated from the Phase 3 study will further support the positive substantiation for VLA15 to date, and we’re looking forward to uniting with the exploration spots across theU.S. and Europe on this important trial.”

Juan Carlos JaramilloM.D., Chief Medical Officer of Valneva, said, “ We’re extremely pleased to reach this important corner in the development of VLA15. Lyme complaint continues to spread, representing a high unmet medical need that impacts the lives of numerous in the Northern Hemisphere. We look forward to farther probing the VLA15 seeker in Phase 3, which will take us a step closer to potentially bringing this vaccine to both grown-ups and children who would profit from it. ”

The randomized, placebo- controlled, Phase 3 VALOR study is planned to enroll roughly,000 actors 5 times of age and aged. The study is being conducted at over to 50 spots located in areas where Lyme complaint is largely aboriginal, including Finland, Germany, the Netherlands, Poland, Sweden and the United States. Actors will admit three boluses of VLA15 180 µg or saline placebo as a primary vaccination series followed by one supporter cure of VLA15 or saline placebo( 11 rate).

Data from the Phase 2 studies continue to demonstrate strong immunogenicity in grown-ups as well as in children, with respectable safety and tolerability biographies in both study populations,2 Pending successful completion of the Phase 3 study, Pfizer could potentially submit a Biologics License operation( BLA) to theU.S. Food and Drug Administration( FDA) and Marketing Authorisation operation( MAA) to the European Medicines Agency( EMA) in 2025.

As per the terms of the collaboration agreement between Pfizer and Valneva, Pfizer will make a$ 25 million corner payment to Valneva upon inauguration of the Phase 3 study.

About VLA15

VLA15 is the only Lyme complaint vaccine seeker presently in clinical development. This investigational multivalent protein subunit vaccine uses an established medium of action for a Lyme complaint vaccine that targets the external face protein A( OspA) of Borrelia burgdorferi, the bacteria that beget Lyme complaint. OspA is a face protein expressed by the bacteria when present in a crack. Blocking OspA inhibits the bacterium’s capability to leave the crack and infect humans. The vaccine covers the six most common OspA serotypes expressed by the Borrelia burgdorferisensu lato species that are current in North America and Europe. VLA15 has demonstrated a strong vulnerable response and satisfactory safety profile inpre-clinical and clinical studies so far. Valneva and Pfizer entered into a collaboration agreement in April 2020 toco-develop VLA15, with updates to the terms within this agreement made in June,4 The terms of the collaboration agreement include a$ 25 million corner payment made to Valneva upon Pfizer’s inauguration of the Phase 3 study. The program was granted Fast Track designation by theU.S. FDA in July2017.5

About Lyme Disease

Lyme complaint is a systemic infection caused by Borrelia burgdorferi bacteria transmitted to humans by infected Ixodes ticks.6 It’s considered the most common vector- borne illness in the Northern Hemisphere.7 While the true prevalence of Lyme complaint is unknown, it’s estimated to annually affect roughly,000 people in the United States and,000 people in Europe,9 Early symptoms of Lyme complaint( similar as a gradationally expanding erythematous rash called Erythema migrans or further nonspecific symptoms like fatigue, fever, headache, mild stiff neck, arthralgia or myalgia) are frequently overlooked or misinterpreted. Left undressed, the complaint can circulate and beget more serious complications affecting the joints( arthritis), the heart( carditis) or the nervous system.9 The medical need for vaccination against Lyme complaint is steadily adding as the geographic footmark of the complaint widens.8

About Pfizer improvements That Change Cases ’ Lives

At Pfizer, we apply wisdom and our global coffers to bring curatives to people that extend and significantly ameliorate their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative drugs and vaccines. Every day, Pfizer associates work across developed and arising requests to advance heartiness, forestallment, treatments and cures that challenge the most stressed conditions of our time. harmonious with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we unite with health care providers, governments and original communities to support and expand access to dependable, affordable health care around the world. For further than 170 times, we’ve worked to make a difference for all who calculate on us.

About Valneva SE

Valneva is a specialty vaccine company concentrated on the development and commercialization of precautionary vaccines for contagious conditions with significant unmet medical need. The Company takes a largely technical and targeted approach to vaccine development and also applies its deep understanding of vaccine wisdom to develop precautionary vaccines addressing these conditions. Valneva has abused its moxie and capabilities both to successfully manipulate two vaccines and to fleetly advance a broad range of vaccine campaigners into and through the clinic, including campaigners against Lyme complaint, the chikungunya contagion and COVID- 19.

Source link: